Global Chronic Lymphocytic Leukemia market 2016-2020


#729302

78pages

Technavio

$ 2500

In Stock

About the Chronic Lymphocytic Leukemia (CLL) Therapeutics Market

Cancer that starts from the hematopoietic stem cells of the bone-marrow is referred to as leukemia. Leukemia can be chronic or acute depending on the maturity of the cells. In addition, based on the bone marrow cells from which the cancer starts, leukemia can be categorized as lymphocytic or myeloid. Hence, leukemia can be broadly classified into four types:
Acute myeloid (or myelogenous) leukemia (AML)
Chronic myeloid (or myelogenous) leukemia (CML)
Acute lymphocytic (or lymphoblastic) leukemia (ALL)
CLL

Technavios analysts forecast the global CLL therapeutics market to grow at a CAGR of 19.16% during the period 2016-2020.

Covered in this report
The report covers the present scenario and the growth prospects of the global CLL therapeutics market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded and generic drugs used to treat and prevent CLL. The report also considers the revenues to be generated from the sales of drugs that are expected to be launched into the market along with the decline in revenues from the genericization of the marketed drugs during the forecast period.

The market is divided into the following segments based on geography:
Americas
APAC
EMEA

Technavio's report, Global Chronic Lymphocytic Leukemia (CLL) Therapeutics Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
F. Hoffman-La Roche
AbbVie
Teva Pharmaceuticals
Gilead Sciences
Novartis
Johnson & Johnson

Other prominent vendors
Altor BioScience
Amgen
Arno Therapeutics
AstraZeneca
Bellicum Pharmaceuticals
Biogen
BioLineRx
Boston Biomedical
Celgene
Emergent BioSolutions
Genzyme
iDD biotech
Immunomedics
Infinity Pharmaceuticals
Innate Pharma
Karyopharm Therapeutics
Ligand Pharmaceuticals
MedImmune
Merck Sharp & Dohme
Molecular Templates Inc.
MorphoSys
Ono Pharmaceutical
Portola Pharmaceuticals
Regeneron Pharmaceuticals
Sunesis Pharmaceuticals
TG Therapeutics
TheraMAB
XEME Biopharma
Xencor
ZIOPHARM Oncology

Market driver
Special regulatory designations
For a full, detailed list, view our report

Market challenge
High cost of therapy
For a full, detailed list, view our report

Market trend
Rise in development of combination therapies
For a full, detailed list, view our report

Key questions answered in this report
What will the market size be in 2020 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analysts time when you purchase this market report. Details are provided within the report.

PART 01: Executive summary
Highlights
PART 02: Scope of the report
Market overview
Top-vendor offerings
PART 03: Market research methodology
Research methodology
Economic indicators
PART 04: Introduction
Key market highlights
PART 05: Disease overview
Understanding the disease
Types of CLL
Symptoms
Diagnosis
Staging
Management
Key buying criteria
PART 06: Pipeline analysis
Acalabrutinib
TG-1101 + ibrutinib
TGR-1202
Venetoclax + obinutuzumab
Venetoclax + rituximab
REVLIMID
Duvelisib
PART 07: Market landscape
Global CLL therapeutics market
Total addressable market for global CLL therapeutics
Five forces analysis
PART 08: Market segmentation by ROA
Oral
Parenteral
PART 09: Market segmentation by type of molecule
Small molecules
Biologics
PART 10: Geographical segmentation
Global CLL therapeutics market by geographical segmentation 2015-2020
CLL therapeutics market in Americas
CLL therapeutics market in EMEA
CLL therapeutics market in APAC
PART 11: Market drivers
Special regulatory designations
Recent drug approvals
Application for expanded indication approvals
Increase in patient pool
PART 12: Impact of drivers
PART 13: Market challenges
High cost of therapy
Availability of chemotherapy and off-label drugs
Adverse effects of drugs
Stringent regulatory guidelines
PART 14: Impact of drivers and challenges
PART 15: Market trends
Joint ventures and partnerships
Patient assistance programs
Rise in development of combination therapies
Growing public awareness
PART 16: Vendor landscape
Competitive scenario
Market share analysis 2015
F. Hoffmann-La Roche
AbbVie
Teva Pharmaceuticals
Johnson & Johnson
Gilead Sciences
Novartis
Other prominent vendors
PART 17: Appendix
List of abbreviations
PART 18: Explore Technavio
List of Exhibits
Exhibit 01: Product offerings
Exhibit 02: Timeline of development of leukemia drugs
Exhibit 03: Snapshot of CLL
Exhibit 04: Types of CLL
Exhibit 05: Main diagnostic procedures to determine presence of CLL
Exhibit 06: Other diagnostic procedures to determine presence of CLL
Exhibit 07: Rai stages of CLL
Exhibit 08: Binet stages of CLL
Exhibit 09: Management of CLL
Exhibit 10: Key buying criteria for CLL drugs
Exhibit 11: Pipeline portfolio: Global CLL therapeutics market
Exhibit 12: Percentage share of drug candidates by stage of development 2015
Exhibit 13: Global CLL therapeutics market 2015-2020 ($ billions)
Exhibit 14: Total addressable market for global CLL therapeutics market 2015-2020 ($ billions)
Exhibit 15: Five forces analysis
Exhibit 16: Segmentation of global CLL therapeutics market by ROA 2015
Exhibit 17: Segmentation of global CLL therapeutics market by type of molecule 2015
Exhibit 18: Segmentation of global CLL therapeutics market based on geography 2015
Exhibit 19: Segmentation of global CLL therapeutics market based on geography 2020
Exhibit 20: Global CLL therapeutics market by geography 2015-2020 ($ millions)
Exhibit 21: Global CLL therapeutics market by geography 2015-2020
Exhibit 22: CLL therapeutics market in Americas 2015-2020 ($ billions)
Exhibit 23: CLL therapeutics market in EMEA 2015-2020 ($ billions)
Exhibit 24: CLL therapeutics market in APAC 2015-2020 ($ millions)
Exhibit 25: Global CLL therapeutics market: YoY growth and revenue based on geography 2015-2020
Exhibit 26: Population aged 60 years and over: World, developed, and developing regions (millions)
Exhibit 27: Impact of drivers
Exhibit 28: Cost of therapy for CLL
Exhibit 29: Impact of drivers and challenges
Exhibit 30: SWOT: MabThera
Exhibit 31: SWOT: Imbruvica
Exhibit 32: SWOT: Treanda
Exhibit 33: SWOT of Zydelig
Exhibit 34: F. Hoffmann-La Roche: YoY growth and revenue generated from total product sales of MabThera/Rituxan (oncology indication) 2013-2015 ($ billions)
Exhibit 35: MabThera/Rituxan geographic segmentation by revenue 2015
Exhibit 36: F. Hoffmann-La Roche: Key takeaways
Exhibit 37: AbbVie: Key takeaways
Exhibit 38: Teva Pharmaceuticals: YoY revenue and growth rate of Treanda 2013-2015 ($ millions)
Exhibit 39: Teva Pharmaceuticals: Key takeaways
Exhibit 40: Johnson & Johnson: YoY revenue comparison of Imbruvica (Global) 2013-2015 ($ millions)
Exhibit 41: Johnson & Johnson: YoY revenue comparison of Imbruvica (US) 2013-2015 ($ millions)
Exhibit 42: Johnson & Johnson: YoY revenue comparison of Imbruvica (ROW) 2013-2015 ($ millions)
Exhibit 43: Johnson & Johnson: Geographic segmentation of Imbruvica 2015
Exhibit 44: Johnson & Johnson: Key takeaways
Exhibit 45: Gilead Sciences: YoY revenue and growth rate of Zydelig 2013-2015 ($ millions)
Exhibit 46: Gilead Sciences: Key takeaways
Exhibit 47: Novartis: Key takeaways